Overview
- TickerHLSQ on NYSE1
- IndustryServices-Prepackaged Software1
- HeadquartersDover, Delaware1
- Incorporated inDE2
- Business address850 New Burton Road, Suite 201, Dover, De 199042
- Filer categoryNon-accelerated filer, Smaller reporting company2
- Legal formCorporation
See how the biggest companies compare on our leaderboards
Fixed cocktail therapy – in this approach a single product containing a fixed number of selected phages is developed to cover a wide range of bacterial strains, thus allowing treatment of broad patient populations with the same product. Fixed cocktails are developed using our platform, in which high throughput screening, directed evolution, and bioinformatic approaches are leveraged to produce an optimal phage cocktail.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.10
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development (R&D) expenses, net | $21.3M | $24.7M |
| General and administrative expenses | $9.6M | $11.8M |
| Gain from early lease termination | -$2.9M | |
| Goodwill impairment | $801.0K | |
| IPR&D impairment | $11.8M | $3.2M |
| Other long-lived assets impairment | $1.7M | $4.0M |
| Operating loss | $41.5M | $44.5M |
| Other expense (income) | $93.0K | -$2.1M |
| Interest expenses | $20.0K | $873.0K |
| Finance expense , net | $724.0K | $919.0K |
| Income from change in fair value of warrants | -$6.1M | -$26.5M |
| Loss before tax | $36.2M | $17.7M |
| Tax expenses | $7.0K | $13.0K |
| Net Loss | $36.2M | $17.7M |
| Basic loss per share of Common Stock (in Dollars per share) | $22.19 | $25.37 |
| Diluted loss per share of Common Stock (in Dollars per share) | $22.19 | $58.31 |
| Weighted average number of shares used in computing basic loss per share of Common Stock (in Shares) | 1.6M shares | 698.9K shares |
| Weighted average number of shares used in computing diluted loss per share of Common Stock (in Shares) | 1.6M shares | 757.7K shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.10
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $4.4M | $16.9M | |
| Restricted cash | $595.0K | $958.0K | |
| Property and equipment, held for sale | $157.0K | ||
| Other current assets | $463.0K | $2.7M | |
| Total current assets | $5.6M | $20.5M | |
| Non-current restricted cash | $161.0K | ||
| Operating lease right-of-use assets | $5.5M | ||
| Property and equipment, net | $5.0M | ||
| In-process Research and development (IPR&D) asset | $208.0K | $12.1M | |
| Total non-current assets | $208.0K | $22.7M | |
| Total Assets | $5.8M | $43.2M | |
| Trade account payables | $3.1M | $1.9M | |
| Current portion of lease liabilities | $1.4M | $1.1M | |
| Other account payables | $1.8M | $5.3M | |
| Total current liabilities | $6.4M | $8.3M | |
| Operating lease liabilities, net of current portion | $8.5M | ||
| Other liabilities | $77.0K | ||
| Warrants | $706.0K | $2.3M | |
| Total non-current liabilities | $706.0K | $10.8M | |
| Preferred Stock, $0.0001 par value; Authorized - 1,000,000 shares as of December 31, 2025 and December 31, 2024. Issued and outstanding 147,512 as of December 31, 2025 and 147,735 shares as of December 31, 2024. | $18.6M | $18.6M | |
| Common stock, $0.0001 par value (Common Stock); Authorized - 750,000,000 shares as of December 31, 2025 and December 31, 2024. Issued and outstanding 1,593,703 and 1,023,010 as of December 31, 2025 and December 31, 2024, respectively. (*) | $7.0K | $6.0K | |
| Additional paid in capital | $197.0M | $186.2M | |
| Accumulated deficit | -$216.9M | -$180.7M | |
| Total Stockholders equity (capital deficiency) | -$1.3M | $24.1M | $3.1M |
| Total liabilities and stockholders equity | $5.8M | $43.2M | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in Shares) | 1.0M shares | 1.0M shares | |
| Preferred stock, shares issued (in Shares) | 147.5K shares | 147.7K shares | |
| Preferred stock, shares outstanding (in Shares) | 147.5K shares | 147.7K shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 750.0M shares | 750.0M shares | |
| Common stock, shares issued (in Shares) | 1.6M shares | 1.0M shares | |
| Common stock, shares outstanding (in Shares) | 1.6M shares | 1.0M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $4.4M | $16.9M | |
| Restricted cash | $595.0K | $958.0K | |
| Property and equipment, held for sale | $157.0K | ||
| Other current assets | $463.0K | $2.7M | |
| Total current assets | $5.6M | $20.5M | |
| Non-current restricted cash | $161.0K | ||
| Operating lease right-of-use assets | $5.5M | ||
| Property and equipment, net | $5.0M | ||
| In-process Research and development (IPR&D) asset | $208.0K | $12.1M | |
| Total non-current assets | $208.0K | $22.7M | |
| Total Assets | $5.8M | $43.2M | |
| Trade account payables | $3.1M | $1.9M | |
| Current portion of lease liabilities | $1.4M | $1.1M | |
| Other account payables | $1.8M | $5.3M | |
| Total current liabilities | $6.4M | $8.3M | |
| Operating lease liabilities, net of current portion | $8.5M | ||
| Other liabilities | $77.0K | ||
| Warrants | $706.0K | $2.3M | |
| Total non-current liabilities | $706.0K | $10.8M | |
| Preferred Stock, $0.0001 par value; Authorized - 1,000,000 shares as of December 31, 2025 and December 31, 2024. Issued and outstanding 147,512 as of December 31, 2025 and 147,735 shares as of December 31, 2024. | $18.6M | $18.6M | |
| Common stock, $0.0001 par value (Common Stock); Authorized - 750,000,000 shares as of December 31, 2025 and December 31, 2024. Issued and outstanding 1,593,703 and 1,023,010 as of December 31, 2025 and December 31, 2024, respectively. (*) | $7.0K | $6.0K | |
| Additional paid in capital | $197.0M | $186.2M | |
| Accumulated deficit | -$216.9M | -$180.7M | |
| Total Stockholders equity (capital deficiency) | -$1.3M | $24.1M | $3.1M |
| Total liabilities and stockholders equity | $5.8M | $43.2M | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in Shares) | 1.0M shares | 1.0M shares | |
| Preferred stock, shares issued (in Shares) | 147.5K shares | 147.7K shares | |
| Preferred stock, shares outstanding (in Shares) | 147.5K shares | 147.7K shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 750.0M shares | 750.0M shares | |
| Common stock, shares issued (in Shares) | 1.6M shares | 1.0M shares | |
| Common stock, shares outstanding (in Shares) | 1.6M shares | 1.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.10
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$36.2M | -$17.7M |
| Depreciation | $2.9M | $1.8M |
| Stock-based compensation | $2.1M | $1.8M |
| Gain from early lease termination | -$2.9M | |
| Finance expense (income), net | $256.0K | -$435.0K |
| Revaluation of contingent consideration | -$77.0K | -$78.0K |
| Income from change in fair value of warrants | -$6.1M | -$26.5M |
| Private Placement Warrants issuance cost | $732.0K | |
| Changes in contract liability | -$2.0M | |
| Loss from sale and disposal of fixed assets, net | $205.0K | $221.0K |
| Goodwill impairment | $801.0K | |
| IPR&D impairment | $11.8M | $3.2M |
| Other long-lived asset impairment | $1.7M | $4.0M |
| Other current assets | $2.2M | $842.0K |
| Trade account payables | $1.2M | -$3.2M |
| Other account payables | -$3.4M | -$984.0K |
| Net change in operating leases | -$74.0K | $316.0K |
| Net cash used in operating activities | -$26.4M | -$37.0M |
| Cash and restricted cash acquired from the APT acquisition | $663.0K | |
| Purchase of property and equipment | -$2.0K | -$30.0K |
| Proceeds from sale of property and equipment | $110.0K | $82.0K |
| Net cash provided by investing activities | $108.0K | $715.0K |
| Issuance of Common Stock under February 2025 SPA | $996.0K | |
| February 2025 SPA issuance costs | -$118.0K | |
| Issuance of Common Warrants under February 2025 SPA | $4.5M | |
| Issuance of Common Stock under Inducement Letter Agreements | $6.5M | |
| Pre-Funded Warrants exercise | $2.0K | $6.0K |
| Issuance of Common Stock under Open Market Sales Agreement, net of issuance costs | $1.3M | $19.0K |
| Repayment of long-term debt | -$10.7M | |
| Issuance of Private Placement Warrants under March 2024 PIPE | $28.7M | |
| Issuance of Redeemable Convertible Preferred Shares under March 2024 PIPE | $21.3M | |
| March 2024 PIPE issuance costs | -$918.0K | |
| Net cash provided by financing activities | $13.2M | $38.4M |
| Increase (decrease) in cash and cash equivalents and restricted cash | -$13.1M | $2.1M |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | $73.0K | $1.0K |
| Cash paid for interest | $20.0K | $1.4M |
| Taxes paid in Israel | $7.0K | $13.0K |
| Lease liability and Operating lease right-of-use asset remeasurement | $2.5M | |
| Derecognition of right-of-use asset as a result of operating lease termination | $1.8M | |
| Derecognition of lease liability as a result of operating lease termination | $4.9M | |
| Property and equipment purchases included in accounts payable | $1.0K | |
| Issuance cost from March 2024 PIPE | $1.3M | |
| Issuance of Common Stock under the APT acquisition | $3.0M | |
| Issuance of Redeemable Convertible Preferred Shares under the APT acquisition | $12.6M | |
| Issuance of Merger Warrants under the APT acquisition | $200.0K | |
| Redeemable Convertible Preferred Shares conversion into shares of Common Stock | $28.0K | $13.8M |
No quarter-by-quarter statement was filed.
Compare Tessera Defense & Homeland Security Inc. with another company
Corporate structure
Tessera Defense & Homeland Security Inc. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Tessera Defense & Homeland Security Inc.
- Mayers Ventures LLC Filed SCHEDULE 13D/A on Tessera Defense & Homeland Security Inc., latest Oct 6, 2026 (2 filings since Sep 17, 2026)
- Mandragola Ltd. Filed SCHEDULE 13G on Tessera Defense & Homeland Security Inc., latest Oct 5, 2026
- T3 Defense Inc. Filed SCHEDULE 13D/A on Tessera Defense & Homeland Security Inc., latest Sep 15, 2026 (3 filings since Apr 10, 2026)
- Cystic Fibrosis Foundation Filed SCHEDULE 13G/A on Tessera Defense & Homeland Security Inc., latest Aug 20, 2026 (6 filings since Mar 8, 2023)
- Nantahala Capital Management, LLC Filed SCHEDULE 13G/A on Tessera Defense & Homeland Security Inc., latest Aug 14, 2026 (4 filings since Nov 13, 2024)
- Centaurus Investments Ltd Filed SCHEDULE 13G/A on Tessera Defense & Homeland Security Inc., latest Aug 13, 2026 (5 filings since Sep 29, 2023)
- James E. Flynn Filed SCHEDULE 13D/A on Tessera Defense & Homeland Security Inc., latest Jun 16, 2026 (8 filings since Mar 22, 2024)
- Alyeska Investment Group, L.P. Filed SCHEDULE 13G/A on Tessera Defense & Homeland Security Inc., latest Feb 17, 2026 (2 filings since May 15, 2025)
- Orin Hirschman Filed SCHEDULE 13G/A on Tessera Defense & Homeland Security Inc., latest Jan 29, 2026 (2 filings since May 8, 2025)
- Reuven Yeganeh Filed SCHEDULE 13D on Tessera Defense & Homeland Security Inc., latest Jan 26, 2026
- Morgan Stanley Filed SCHEDULE 13G/A on Tessera Defense & Homeland Security Inc., latest Aug 7, 2025 (2 filings since Aug 5, 2025)
- OrbiMed Israel BioFund GP Limited Partnership Filed SCHEDULE 13D/A on Tessera Defense & Homeland Security Inc., latest Jun 23, 2025 (6 filings since Mar 17, 2023)
- Tessera Defense & Homeland Security Inc. Dover, Delaware
- Adaptive Phage Therapeutics, LLC Subsidiary · Delaware, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Tessera Defense & Homeland Security Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Machinery and equipment | $5.0M10 Dec 31, 2025 | $5.5M10 Dec 31, 2024 | −8.2% |
| Furniture and fixtures | $257.0K10 Dec 31, 2025 | $318.0K10 Dec 31, 2024 | −19.2% |
| Computer equipment and software | $304.0K10 Dec 31, 2025 | $302.0K10 Dec 31, 2024 | +0.7% |
| Leasehold improvements | $4.4M10 Dec 31, 2024 | $3.0M9 Dec 31, 2023 | +48.8% |
| Property and equipment, before depreciation | $5.6M10 Dec 31, 2025 | $10.5M10 Dec 31, 2024 | −47.0% |
| Accumulated depreciation | $5.4M10 Dec 31, 2025 | $5.5M10 Dec 31, 2024 | −1.2% |
| Property and equipment, net | $5.0M10 Dec 31, 2024 | $3.9M9 Dec 31, 2023 | +29.3% |
| Operating-lease assets (leased space) | $5.5M10 Dec 31, 2024 | $3.5M9 Dec 31, 2023 | +56.1% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $4.4M10 Dec 31, 2025 | $16.9M10 Dec 31, 2024 | −74.1% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $801.0K10 Dec 31, 2024 |
Properties, in its own words
We are currently a virtual company and do not currently lease or own any physical space. We maintain a mailing address at 850 New Burton Road, Suite 201, Dover, DE 19904.
In November 2025, our lease for our corporate headquarters in Ness Ziona, Israel, was terminated.
The rest of Item 2
In addition, the lease agreement for our office and laboratory facility in Gaithersburg, Maryland, was amended and terminated as of December 31, 2025.
Item 2 of the 10-K filed Feb 19, 2026.4
Leadership
Who has led Tessera Defense & Homeland Security Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chair
Chief financial officer
20202025
- Chief executive officerJonathan Eitan Solomon Nov 7, 2019 to now14
- ChairGbolahan Amusa Dec 14, 2018 to Dec 14, 201815
- Chief financial officerAvraham Gabay Dec 11, 2023 to Dec 11, 202316
- Chief financial officerMarina Wolfson Aug 24, 2022 to Dec 11, 202317
- Chief financial officerGeorge Kaufman Dec 14, 2018 to Dec 14, 201818
Board members and other officers (33)
- Principal Financial OfficerMarina Wolfson Jan 15, 2020 to Mar 31, 202219
- Chief Business OfficerAssaf Oron Nov 7, 2019 to now20
- VP of Platform Research&Devel.Inbar Gahali-Sass Nov 7, 2019 to Nov 7, 201921
- Chief Development OfficerMerav Bassan Nov 7, 2019 to now22
- Vice President of DevelopmentMyriam Golembo Nov 7, 2019 to Nov 7, 201923
- Chief Medical OfficerSailaja Puttagunta Nov 7, 2019 to Apr 1, 202124
- Board memberReuven Yeganeh Jan 16, 2026 to now25
- Board memberLiat Cohavi Bidas Mar 3, 2026 to now26
- Board memberJames E. Flynn Mar 19, 2024 to now27
- Board memberMgmt Hif L.p. Deerfield Mar 19, 2024 to now27
- Board memberGregory Louis Merril Mar 21, 2024 to now28
- Board memberJesse Goodman Mar 21, 2024 to now29
- Board memberJonathan S. Leff Mar 21, 2024 to now30
- Board memberSusan Blum Apr 15, 2024 to now31
- Board memberJason M. Marks May 19, 2023 to Aug 23, 202332
- Board memberMichael E. Dambach May 19, 2023 to Aug 23, 202333
- Board memberGbolahan Amusa Mar 27, 2020 to Mar 31, 202234
- Board memberAlan Charles Moses Oct 5, 2020 to now35
- Board memberPaul J. Sekhri Oct 5, 2020 to Jul 30, 202136
- Board memberErez Chimovits Nov 7, 2019 to Mar 27, 202037
- Board memberJonathan Eitan Solomon Nov 7, 2019 to now14
- Board memberRobbie Woodman Nov 7, 2019 to Nov 7, 201938
- Board memberRussell Greig Nov 7, 2019 to now39
- Board memberYaron Breski Nov 7, 2019 to Mar 27, 202040
- Board memberUri Ben-Or Nov 8, 2019 to Nov 8, 201941
- Board memberLynne Marie Sullivan Nov 12, 2019 to Mar 3, 202342
- Board memberIsrael Biofund Gp Limited Partnership Orbimed Dec 9, 2019 to Dec 20, 201943
- Board memberEric Kusseluk Dec 14, 2018 to Dec 14, 201844
- Board memberGeorge Kaufman Dec 14, 2018 to Dec 14, 201818
- Board memberMatthew Rossen Dec 14, 2018 to Dec 14, 201845
- Board memberRichard Giroux Dec 14, 2018 to Dec 14, 201846
- Board memberYehuda Michael Rice Dec 14, 2018 to Dec 14, 201847
- Board memberElliot Gnedy Dec 21, 2018 to Dec 21, 201848
Named in SEC Form D filings
People the company listed in its private-offering notices.
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Adaptive Phage Therapeutics, LLC Delaware, USA3
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
Timeline
- Oct 13, 20268-K Unregistered sale of shares; Other events52
- Oct 7, 20268-K Executive or director change; Regulation FD disclosure53
- Oct 5, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares54
- Sep 29, 20268-K Regulation FD disclosure55
- Sep 25, 20268-K Entered a material agreement56
- Sep 22, 20268-K Entered a material agreement; Unregistered sale of shares57
- Sep 15, 20268-K Bylaws or fiscal year changed; Regulation FD disclosure58
- Sep 9, 20268-K Bylaws or fiscal year changed59
- Sep 1, 20268-K Other events60
- Sep 1, 20268-K Other events61
- Aug 28, 20268-K Other events62
- Aug 25, 20268-K Shareholder vote63
- Nov 7, 2019New chief executive Jonathan Eitan Solomon becomes CEO14
Calendar
Coming up
- Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($55.13) a share, on Nov 12, 2025.64
When it reported results
- Nov 12, 2025Reported quarterly or annual results65
- Aug 13, 2025Reported quarterly or annual results66
- May 15, 2025Reported quarterly or annual results67
- Mar 25, 2025Reported quarterly or annual results68
- Nov 14, 2024Reported quarterly or annual results69
- Apr 3, 2024Reported quarterly or annual results70
- Nov 14, 2023Reported quarterly or annual results71
- Aug 9, 2023Reported quarterly or annual results72
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
377 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 100 major events, 98 insider forms, 56 large holders, 5 private raises, 96 other. The latest 20:
- Oct 13, 20268-K CURRENT REPORT EDGAR
- Oct 8, 2026DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
- Oct 8, 2026DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
- Oct 7, 20268-K CURRENT REPORT EDGAR
- Oct 6, 2026DEF 14A DEFINITIVE PROXY STATEMENT EDGAR
- Oct 6, 2026SCHEDULE 13D/A EDGAR
- Oct 5, 2026SCHEDULE 13G EDGAR
- Oct 5, 20268-K CURRENT REPORT EDGAR
- Sep 29, 20268-K CURRENT REPORT EDGAR
- Sep 25, 2026PRE 14A PRELIMINARY PROXY STATEMENT EDGAR
- Sep 25, 20268-K CURRENT REPORT EDGAR
- Sep 22, 20268-K CURRENT REPORT EDGAR
- Sep 17, 2026SCHEDULE 13D EDGAR
- Sep 15, 20268-K CURRENT REPORT EDGAR
- Sep 15, 2026SCHEDULE 13D/A EDGAR
- Sep 9, 20268-K CURRENT REPORT EDGAR
- Sep 1, 20268-K CURRENT REPORT EDGAR
- Sep 1, 20268-K/A AMENDMENT NO. 1 TO FORM 8-K EDGAR
- Aug 28, 20268-K CURRENT REPORT EDGAR
- Aug 25, 20268-K CURRENT REPORT EDGAR
The 377 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
72 open-market trades by officers, directors and large owners since October 2021: 4 buys and 68 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 17, 2026 | Yeganeh ReuvenDirector | Sale | 530,000 | $5.00 | $2.6M | Form 4 |
| Mar 16, 2026 | Yeganeh ReuvenDirector | Sale | 450,000 | $5.00 | $2.2M | Form 4 |
| Mar 13, 2026 | Yeganeh ReuvenDirector | Sale | 370,000 | $5.00 | $1.9M | Form 4 |
| Mar 12, 2026 | Yeganeh ReuvenDirector | Sale | 300,000 | $5.00 | $1.5M | Form 4 |
| May 15, 2024 | GORDON CARL L10% owner | Sale | 24,344 | $0.38 | $9.3K | Form 4 |
| Nov 29, 2023 | Oron AssafChief Business Officer | Sale | 10,914 | $0.37 | $4.1K | Form 4 |
| May 22, 2023 | Oron AssafChief Business Officer | Buy | 3,192 | $0.27 | $862 | Form 4 |
| May 19, 2023 | Oron AssafChief Business Officer | Buy | 6,521 | $0.28 | $1.8K | Form 4 |
| May 18, 2023 | Oron AssafChief Business Officer | Buy | 1,201 | $0.27 | $324 | Form 4 |
| Feb 27, 2023 | OrbiMed Israel GP Ltd.10% owner | Buy | 348,000 | $0.25 | $87.0K | Form 4 |
| Nov 4, 2022 | Ugwumba Chidozie | Sale | 1,501 | $0.38 | $570 | Form 4 |
| Nov 3, 2022 | Ugwumba Chidozie | Sale | 2,000 | $0.37 | $740 | Form 4 |
| Nov 2, 2022 | Ugwumba Chidozie | Sale | 2,416 | $0.36 | $870 | Form 4 |
| Nov 1, 2022 | Ugwumba Chidozie | Sale | 1,300 | $0.36 | $468 | Form 4 |
| Oct 31, 2022 | Ugwumba Chidozie | Sale | 3,300 | $0.37 | $1.2K | Form 4 |
| Oct 28, 2022 | Ugwumba Chidozie | Sale | 1,526 | $0.36 | $549 | Form 4 |
| Oct 27, 2022 | Ugwumba Chidozie | Sale | 1,505 | $0.36 | $542 | Form 4 |
| Oct 26, 2022 | Ugwumba Chidozie | Sale | 12,500 | $0.35 | $4.4K | Form 4 |
| Oct 25, 2022 | Ugwumba Chidozie | Sale | 3,072 | $0.37 | $1.1K | Form 4 |
| Oct 24, 2022 | Ugwumba Chidozie | Sale | 5,900 | $0.35 | $2.1K | Form 4 |
All 72 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Mayers Ventures LLCSCHEDULE 13D/A, 2 filings Sep 17, 2026 to Oct 6, 202673
- Mandragola Ltd.SCHEDULE 13G, 1 filing Oct 5, 202674
- T3 Defense Inc.SCHEDULE 13D/A, 3 filings Apr 10, 2026 to Sep 15, 202675
- Cystic Fibrosis FoundationSCHEDULE 13G/A, 6 filings Mar 8, 2023 to Aug 20, 202676
- Nantahala Capital Management, LLCSCHEDULE 13G/A, 4 filings Nov 13, 2024 to Aug 14, 202677
- Centaurus Investments LtdSCHEDULE 13G/A, 5 filings Sep 29, 2023 to Aug 13, 202678
- James E. FlynnSCHEDULE 13D/A, 8 filings Mar 22, 2024 to Jun 16, 202679
- Alyeska Investment Group, L.P.SCHEDULE 13G/A, 2 filings May 15, 2025 to Feb 17, 202680
- Orin HirschmanSCHEDULE 13G/A, 2 filings May 8, 2025 to Jan 29, 202681
- Reuven YeganehSCHEDULE 13D, 1 filing Jan 26, 202682
- Morgan StanleySCHEDULE 13G/A, 2 filings Aug 5, 2025 to Aug 7, 202583
- OrbiMed Israel BioFund GP Limited PartnershipSCHEDULE 13D/A, 6 filings Mar 17, 2023 to Jun 23, 202584
- AMR Action Fund, L.P.SC 13G/A, 2 filings Mar 25, 2024 to Nov 13, 202485
- John Howard Burbank Iii.SC 13G/A, 2 filings Jun 23, 2023 to Nov 4, 202486
- MMCAP International Inc. SPCSC 13G/A, 3 filings Feb 4, 2022 to Feb 13, 202487
- Johnson & JohnsonSC 13G/A, 1 filing Feb 2, 202488
- Chidozie UgwumbaSC 13G/A, 3 filings Feb 14, 2022 to Feb 13, 202389
- Takeda Pharmaceutical CompanySC 13G/A, 2 filings Oct 18, 2021 to Aug 5, 202290
- Thomas Layton WaltonSC 13G, 1 filing Feb 14, 202291
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Jonathan Solomon | $453.3K | $1.4M92 | |
| 2025 | Dr. Merav Bassan | $285.0K | $642.3K92 | |
| 2025 | Marina Wolfson | $249.1K | $553.5K92 | |
| 2024 | Chief Executive Officer | $415.1K | $1.1M92 | |
| 2024 | Chief Development Officer | $265.8K | $533.0K92 | |
| 2024 | Chief Financial Officer | $179.9K | $351.6K92 |
Funding
Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.
- Private raises (Form D) $72.3M
Figures by year
| Year | Private raises (Form D) | Total |
|---|---|---|
| 2026 | $3.3M | $3.3M |
| 2024 | $61.5M | $61.5M |
| 2023 | $1.5M | $1.5M |
| 2021 | $6.0M | $6.0M |
Private raises
Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.
- Jan 13, 2026Raised $3.3 million in a private offering of equity50 Form D: 1 investor so far Form D
- Mar 15, 2024Raised $61.5 million in a private offering of equity49 Form D: 34 investors so far Form D
- Feb 27, 2023Raised $1.5 million in a private offering of equity93 Form D: $7.5 million offered in all Form D
- Dec 21, 2021Raised $3 million in a private offering of equity51 Form D: $5 million offered in all Form D
- Oct 14, 2021Raised $3 million in a private offering of equity94 Form D: 1 investor so far Form D
SEC filer profile
How Tessera Defense & Homeland Security Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARTessera Defense & Homeland Security Inc.1
- CIK0001739174
- Employer ID (EIN)82-33640204
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)7372 Services-Prepackaged Software1
- SEC reviewing officeOffice of Technology, Division of Corporation Finance1
- Business address850 New Burton Road, Suite 201, Dover, DE 199041
- Phone972 5456109351
- Shares outstanding26,723,870 as of Aug 18, 202611
- Public float$11.9M as of Jun 30, 20254
- AuditorKesselman & Kesselman, Tel-Aviv, Israel PCAOB ID 1309; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceMay 4, 20181
- Filings580 in all: 8-K (131), 4 (121), 3 (42), 10-Q (23), DEFA14A (21), SC 13G/A (20), CORRESP (16), UPLOAD (16)1
All 50 form types
DEF 14A (14), SC 13G (14), 4/A (11), EFFECT (11), SCHEDULE 13G/A (11), PRE 14A (9), SCHEDULE 13D/A (9), 10-K (8), S-8 (8), 424B5 (7), SC 13D/A (7), 424B3 (6), 8-K/A (6), S-3 (6), SCHEDULE 13G (6), D (5), NT 10-Q (4), S-1 (4), S-1/A (4), ARS (3), DRS (3), DRS/A (3), PRER14A (3), S-3/A (3), SCHEDULE 13D (3), 10-K/A (2), 25-NSE (2), SC 13D (2), SC TO-I/A (2), SEC STAFF LETTER (2), 15-12G (1), 424B4 (1), 5 (1), 8-A12B (1), CERT (1), DEFM14A (1), DRSLTR (1), NT 10-K (1), POS AM (1), PREM14A (1), S-8 POS (1), SC TO-I (1)
- Latest filingsAnnual report (10-K) Feb 19, 2026
Quarterly report (10-Q) Aug 19, 2026
Proxy statement (DEF 14A) Oct 6, 2026
Latest 8-K (8-K) Oct 13, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common stock, $0.0001 par value | PHGE | NYSE American |
From the cover page of the 10-K filed Feb 19, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks Tessera Defense & Homeland Security Inc. names in Item 1A of its 10-K filed Feb 19, 2026: 60 risks under these headings, as written.4
- Risks Related to Our Business, Technology and Industry
- Our exploration of strategic alternatives could adversely affect our business and our stock price.
- If we fail to obtain stockholder approval required under NYSE American rules in connection with the 2025 Second SPA, we could be unable to access sufficient financing, and could be required to hold additional stockholder meetings and incur significant costs, potentially leading to the delisting of our Common Stock.
- We are a clinical-stage company and have incurred losses since our inception. Subject to availability of sufficient financial and other resources, we anticipate that we will continue to incur significant expenses, and we will continue to incur significant losses for the foreseeable future.
- We will need to raise additional capital in the future to support our operations which may not be available at terms that are favorable to us and might cause significant dilution to our stockholders or increase our debt towards third parties.
- If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.
- Our financial statements contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.
- We are seeking to develop product candidates using phage technology, an approach for which it is difficult to predict the time and cost of development. To our knowledge, as of the date of this Annual Report, no bacteriophage has thus far been approved as a drug in the United States or in the European Union.
- Our product candidates must undergo clinical testing which may fail to demonstrate the requisite safety and efficacy for drug products, or safety, purity, and potency for biologics, and any of our product candidates could cause adverse effects, which would substantially delay or prevent regulatory approval and/or commercialization.
- Ongoing geopolitical instability have adversely affected and may continue to adversely affect our business, including our clinical trials.
- Changes in trade policy, including the imposition of tariffs, may adversely affect our business, results of operations and financial condition.
- If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates for therapeutic indications, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our future ability to generate revenue will be materially impaired.
The other 49 risks
- We have never generated any revenue from product sales and may never be profitable or, if achieved, may not sustain profitability.
- We are seeking to develop product candidates to treat medical conditions related to the presence of certain bacteria. Our success is largely dependent on a broad degree of market acceptance, and in the case of drug products, physician adoption and use, which are necessary for commercial success.
- Obtaining high titers for specific phage cocktails necessary for our preclinical and clinical testing may be difficult and time-consuming.
- Results from preclinical studies of our product candidates may not be predictive of the results of clinical trials or later stage clinical development.
- If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
- Delays, or clinical holds, in our clinical trials could result in us not achieving anticipated developmental milestones when expected, increased costs and delays in our ability to obtain regulatory approval for and commercialization of our product candidates.
- Our current or future product candidates may cause adverse effects that could halt their clinical development, prevent their approval or marketing, limit their commercial potential or result in significant negative consequences.
- We have not completed composition development of our product candidates.
- We must continue to develop manufacturing processes for our product candidates, and any delay in doing so, or our inability to do so, would result in delays in our clinical trials.
- If our competitors are able to develop and market products that are more effective, safer or more affordable than ours, or obtain marketing approval before we do, our commercial opportunities may be limited.
- We may not be successful in our efforts to identify or discover additional product candidates.
- Legal requirements as well as ethical and social concerns about synthetic biology and genetic engineering could limit or prevent the use of our technologies and limit our revenues.
- We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
- There is a substantial risk of product liability claims in our business. If we do not obtain sufficient liability insurance, a product liability claim could result in substantial liabilities to us.
- Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
- Our limited operating history compared to the long time it takes to develop phage based products may make it difficult to evaluate the success of our business to date and to assess our future viability.
- We may need to grow the size of our organization and may experience difficulties in managing this growth.
- Risks Related to Government Regulation and Government
- Our product candidates are subject to significant regulatory approval requirements, including the risk of clinical holds, which could delay, prevent or limit our ability to market or develop our product candidates.
- Failure to comply with health and data protection laws and regulations could lead to claims, government enforcement actions (which could include civil or criminal penalties), regulatory actions, private litigation and/or adverse publicity and could negatively affect our operating results and business.
- Our relationships with healthcare providers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
- The FDA and other equivalent foreign regulatory agencies may implement additional regulations or restrictions on the development and commercialization of products which act on the microbiome, which may be difficult to predict.
- Even if we receive regulatory approval of any product candidates for therapeutic indications, we will be subject to ongoing regulatory compliance obligations and continued regulatory review, which may result in significant additional expense. Additionally, any of our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.
- We may conduct clinical trials for our product candidates outside the United States, and the FDA may not accept data from such trials.
- Any products that we may develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which could make it difficult for us to sell any product candidates or therapies profitably.
- Ongoing health care legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.
- Disruptions at the FDA and other government agencies and entities, such as the U.S. Department of Defense, caused by funding shortages, government shutdowns, global health concerns or other causes could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.
- We are subject to certain U.S. and foreign anticorruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.
- Risks Related to our Licensed and Co-Owned Intellectual Property
- We are highly dependent on intellectual property licensed from third parties, and termination or limitation of any of these licenses could result in the loss of significant rights and materially harm our business.
- We are dependent on patents and proprietary technology. If we fail to adequately protect this intellectual property or if we otherwise do not have exclusivity for the marketing of our products, our ability to commercialize products could suffer.
- Our rights to develop and commercialize our product candidates and proprietary product platform may be subject, in part, to the terms and conditions of current and future licenses granted to us by others.
- If we infringe the rights of third parties, we could be prevented from selling products, forced to pay damages and/or royalties, and forced to defend against litigation.
- We may not be successful in obtaining, through acquisitions, in-licenses or otherwise, necessary rights to our product candidates, proprietary product platform technologies or other technologies.
- We rely on our proprietary product platform to identify phage-based therapies. Our competitive position could be materially harmed if our competitors develop a similar platform and develop rival product candidates.
- We rely on trade secrets and other forms of non-patent intellectual property protection. If we are unable to protect our trade secrets, other companies may be able to compete more effectively against us.
- If we are sued for infringing intellectual property rights of third parties or if we are forced to engage in an interference proceeding, it will be costly and time-consuming, and an unfavorable outcome in that litigation or interference would have a material adverse effect on our business.
- Risks Related to Our Reliance on Third Parties
- We rely, and continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.
- Third-party relationships are important to our business. If we are unable to maintain our collaborations or enter into new relationships, or if these relationships are not successful, our business could be adversely affected.
- We may not be successful in maintaining or establishing collaborations, which could adversely affect our ability to develop and, if required regulatory approvals are obtained, commercialize our product candidates.
- Risks Related to Manufacturing and Supply
- We rely on third parties to manufacture our clinical supply of product candidates and we intend to rely on third parties to produce and process our products, if approved.
- Our product candidates rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.
- Risks Related to Our Common Stock
- A significant number of shares of our Common Stock are subject to issuance upon exercise of outstanding warrants and options or conversion of our Convertible Preferred Stock, which upon such exercise or conversion, as applicable, may result in dilution to our security holders.
- We have never paid dividends on our Common Stock, and we do not anticipate paying any cash dividends on our Common Stock in the foreseeable future.
- We may be unable to maintain the listing of our securities in the future.
- The market price of our Common Stock and other securities may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our Common Stock.
- As a “smaller reporting company” we are permitted to provide less disclosure than larger public companies, which may make our Common Stock less attractive to investors.
- General Risk Factors
- Our success depends, in part, on our ability to retain key executives and to attract, retain and motivate qualified personnel.
- Expectations relating to environmental, social and governance (ESG) programs may impose additional costs and expose us to new risks.
- Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.
- We incur significant costs operating as a public company.
Legal proceedings
We may be subject to legal proceedings, investigations and claims incidental to the conduct of our business from time to time. We are not currently a party to any material litigation or other material legal proceedings brought against us.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15SEC EDGARGbolahan Amusa, Chair
- 16
- 17
- 18
- 19
- 20SEC EDGARAssaf Oron, Chief Business Officer
- 21
- 22
- 23
- 24
- 25SEC EDGARReuven Yeganeh, Board member
- 26SEC EDGARLiat Cohavi Bidas, Board member
- 27SEC EDGARJames E. Flynn, Board member
- 28SEC EDGARGregory Louis Merril, Board member
- 29SEC EDGARJesse Goodman, Board member
- 30SEC EDGARJonathan S. Leff, Board member
- 31SEC EDGARSusan Blum, Board member
- 32SEC EDGARJason M. Marks, Board member
- 33SEC EDGARMichael E. Dambach, Board member
- 34SEC EDGARGbolahan Amusa, Board member
- 35SEC EDGARAlan Charles Moses, Board member
- 36SEC EDGARPaul J. Sekhri, Board member
- 37SEC EDGARErez Chimovits, Board member
- 38SEC EDGARRobbie Woodman, Board member
- 39SEC EDGARRussell Greig, Board member
- 40SEC EDGARYaron Breski, Board member
- 41SEC EDGARUri Ben-Or, Board member
- 42SEC EDGARLynne Marie Sullivan, Board member
- 43
- 44SEC EDGAREric Kusseluk, Board member
- 45SEC EDGARMatthew Rossen, Board member
- 46SEC EDGARRichard Giroux, Board member
- 47SEC EDGARYehuda Michael Rice, Board member
- 48SEC EDGARElliot Gnedy, Board member
- 49
- 50
- 51
- 52
- 53
- 54
- 55SEC EDGARRegulation FD disclosure
- 56SEC EDGAREntered a material agreement
- 57
- 58
- 59SEC EDGARBylaws or fiscal year changed
- 60SEC EDGAROther events
- 61SEC EDGAROther events
- 62SEC EDGAROther events
- 63SEC EDGARShareholder vote
- 64NasdaqNasdaq calendar
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94